Co-Diagnostics Inc

NASDAQ CODX

Data sourced from iex and EODHD
Download Data

Co-Diagnostics Inc Cash Flow Coverage Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending June 30, 2023: -37.74%

Co-Diagnostics Inc Cash Flow Coverage Ratio 5 year CAGR is -37.74% for the Trailing 12 Months (TTM) ending June 30, 2023. The cash flow coverage ratio evaluates a company's ability to cover its interest expense with its operating cash flow after deducting capital expenditures. It is calculated by dividing the difference between operating cash flow and capital expenditures by interest expense. This ratio indicates the company's ability to generate enough cash flow to service its interest payments. A higher ratio signifies better coverage and financial stability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Co-Diagnostics Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 2.08, a -99.75% change year over year.
  • Co-Diagnostics Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 832.21, a 63.16% change year over year.
  • Co-Diagnostics Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 510.04, a 101.23% change year over year.
  • Co-Diagnostics Inc Cash Flow Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was -41,501.82, a -246,237.05% change year over year.
NASDAQ: CODX

Co-Diagnostics Inc

CEO Mr. Dwight H. Egan
IPO Date July 12, 2017
Location United States
Headquarters 2401 South Foothill Drive, Salt Lake City, UT, United States, 84109
Employees 155
Sector Healthcare
Industry Medical devices
Description

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Similar companies

CLPT

Clearpoint Neuro Inc

NA

NA

SRDX

SurModics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email